Probiodrug AG announced financial results for the year ended 31 December 2017. For the year, under IFRS, the company reported operating loss of EUR 9,961,000 against EUR 13,777,000 for the last year. Net loss for the period was EUR 8,009,000 against EUR 13,891,000 for the last year. Loss per basic and diluted share was EUR 0.98 against EUR 1.82 for the last year. Cash flows used in operating activities was EUR 12,117,000 against EUR 13,255,000 for the last year.

The company projects a net loss for the financial year 2018 which, based on the current budget, is expected to be lower than that of 2017.